This site is intended for US Healthcare Professionals. Menu This site is intended for US Healthcare Professionals.
Welcome,

REGISTRATION


STEP 1 STEP 2

An Allergan account number is required for registration. Please enter your Allergan account number.



NEXT CANCEL

Where can I find my Allergan account number?

Your Allergan account number is the “ship-to” account number listed on your invoices. For assistance, contact your Allergan Business Development Manager or Allergan Customer Service at 800-377-7790.

To set up an Allergan account, please call 844-NEW-2AGN (844-639-2246).

REGISTRATION


STEP 1 STEP 2

All fields are required for registration unless indicated otherwise.

Please see our Privacy Statement for more information.

*Nonrequired field.
Credentials*
State license number*
Credentials*
State license number*
Back Cancel

Thank you for registering.

Continue to KYBELLA® educational video.



CONTINUE
×

ABOUT KYBELLA®

The first-of-its-kind FDA-approved injectable, KYBELLA® is a nonsurgical option to improve the appearance of submental fullness in adults.

More More
before-and-after_new
 

Individual results may vary.

Before & Afters

See the noticeable results and improved chin profile of patients treated with KYBELLA®.

View View
before-and-after-mobile
 

Individual results may vary.

INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

Reference: 1. KYBELLA® Prescribing Information, January 2018.

Forgot Password




GET NEW PASSWORD
×

New Password


Xxxxxxx@xxxxxx.com




SUBMIT
×